

实验研究案例

Probiotics for the Prevention of Gestational
Diabetes Mellitus in Overweight and
Obese Women: Findings From the
SPRING Double-
blind Randomized Controlled Trial

研究案例目录

- 研究背景
- 研究目的
- 研究设计
- 研究方法
- 研究结果
- 结论

研究背景

肠道菌群与宿主的代谢密切相关。因此，在妊娠期期间服用益生菌可能会预防妊娠糖尿病 (GDM)。然而目前还没有在超重和肥胖孕妇中进行过相关研究。

研究目的

确定超重和肥胖孕妇在孕中期口服益生菌(鼠李糖乳杆菌和动物双歧杆菌亚种乳酸菌[BB-12])能否预防GDM的发生, 为GDM的防治提供流行病学依据。

研究设计

- ◆ 随机双盲对照试验（RCT）
- ◆ 研究对象及干预方法：在澳大利亚布里斯班对超重和肥胖孕妇进行的益生菌 VS. 安慰剂的双盲随机对照试验。
- ◆ 主要结局变量：GDM
- ◆ 次要结局变量：包括产妇和新生儿并发症、产妇血压和BMI，以及婴儿身体状况

研究方案

在孕20周前，采用随机数方法将411名超重/肥胖孕妇随机分为2组，分别服用益生菌（鼠李糖乳杆菌+动物双歧杆菌乳亚种BB-12）或安慰剂，每天服用一次，一直干预至分娩。

在孕28周时进行口服葡萄糖耐量试验进行GDM诊断，并收集孕妇其他妊娠结局（孕期体重增长、子痫前期、妊娠期高血压、剖宫产等）及新生儿结局资料（早产儿、新生儿黄疸、新生儿低血糖、出生体重、小于胎龄儿、大于胎龄儿、死产、出生缺陷等）。分析口服益生菌干预对孕妇血糖、GDM及其他结局的影响。

技术路线




Figure 1—Eligibility, randomization, and follow-up. (A high-quality color representation of this figure is available in the online issue.)

研究结果

安慰剂组孕妇GDM的发病率为12.3%，而益生菌组GDM发病率为18.4%，两组间无显著差异。

在口服葡萄糖耐量试验中，益生菌组孕妇的平均空腹血糖显著高于安慰剂组；

研究结果

益生菌组子痫前期的发病率为9.2% ， 安慰剂组的为4.9%， 两组无显著差异；

益生菌组孕妇体重过度增长的比例为32.5%， 显著低于安慰剂组的（46%）；

益生菌组孕妇产子代小于胎龄儿的发生率为2.4%， 显著低于安慰剂组的（6.5%）。

Primary outcome: GDM at 28 weeks' gestation

	Summary		Effect (95% CI)†	P‡
	Placebo (<i>n</i> = 204)	Probiotics (<i>n</i> = 207)		
GDM*	25 (12.3)	38 (18.4)	1.62 (0.91–2.89)	0.10
Fasting glucose, mmol/L [mg/dL]†§	4.3 (0.45) [77.5 (8.1)]	4.4 (0.5) [79.3 (9.0)]	0.085 (0.00053–0.17) [1.53 (0.0095–3.06)]	0.049
1-h glucose, mmol/L [mg/dL]†§	7.5 (1.6) [135.1 (28.8)]	7.6 (1.8) [136.9 (32.4)]	0.052 (–0.27 to 0.37) [0.94 (–4.86 to 6.66)]	0.75
2-h glucose, mmol/L [mg/dL]†§	6.3 (1.4) [113.5 (25.2)]	6.4 (1.5) [115.3 (27.0)]	0.13 (–0.15 to 0.40) [2.34 (–2.70 to 7.20)]	0.37

*Summary: *n* (%). Effect: odds ratio with placebo as referent. †Summary: mean (SD). ‡Effect: difference of means. Adjusted for BMI (25–29, 30–39, and 40+ kg/m²) and patient center (RBWH, Redcliffe, Mater). §*n*_{placebo} = 202; *n*_{probiotics} = 205.

Secondary outcomes

Secondary outcomes	n		Summary		Effect (95% CI)‡	P
	Placebo	Probiotic	Placebo	Probiotic		
Mother						
Preeclampsia*	203	206	10 (4.9)	19 (9.2)	2.00 (0.89–4.50)	0.09
Gestational hypertension*	203	206	11 (5.4)	10 (4.9)	0.86 (0.35–2.09)	0.74
Hypertensive disorders of pregnancy*	203	206	26 (12.8)	34 (16.5)	1.35 (0.76–2.37)	0.30
Caesarean*	204	207	80 (39.2)	73 (35.3)	0.85 (0.56–1.27)	0.41
In labor/intrapartum/emergency caesarean*	78	73	36 (46.2)	33 (45.2)	1.00 (0.52–1.93)	1.00
Induced labor*	202	206	62 (30.7)	74 (35.9)	1.23 (0.81–1.87)	0.34
28 weeks systolic BP (mmHg)†	196	197	110.3 (10.6)	110.4 (9.9)	0.003 (–1.90 to 1.91)	1.00
28 weeks diastolic BP (mmHg)†	196	197	65.0 (7.6)	66.4 (7.8)	1.36 (–0.11 to 2.84)	0.070
36 weeks systolic BP (mmHg)†	177	169	114.0 (10.6)	115.7 (11.3)	1.62 (–0.66 to 3.90)	0.16
36 weeks diastolic BP (mmHg)†	177	169	70.5 (8.3)	70.9 (9.8)	0.51 (–1.35 to 2.37)	0.59
36 weeks weight gain from baseline (kg)†	176	169	9.5 (4.3)	8.9 (5.3)	–0.55 (–1.55 to 0.45)	0.28
Excess weight gain*	176	169	81 (46)	55 (32.5)	0.56 (0.36–0.87)	0.01
Inadequate weight gain			28 (15.9)	34 (20.1)		
Weight gain per week from baseline to 36 weeks (kg/week)	176	169	0.40 (0.19)	0.37 (0.23)	–0.03 (–0.08 to 0.01)	0.17
Infant						
Gestational age at delivery (weeks)	180	193	39.32 (1.75)	39.14 (1.88)	–0.18 (–0.55 to 0.19)	0.34
Very preterm (<34 weeks)*	180	193	3 (1.7)	5 (2.6)	1.59 (0.37–6.85)	0.53
Preterm (<37 weeks)*	180	193	12 (6.7)	17 (8.8)	1.36 (0.63–2.96)	0.43
Special care unit admission*	199	207	43 (21.6)	42 (20.3)	0.92 (0.57–1.50)	0.75
Jaundice*	201	205	40 (19.9)	35 (17.1)	0.82 (0.50–1.36)	0.45
Birth injury*	198	203	1 (0.5)	1 (0.5)	—	—
Hypoglycemia*	200	202	27 (13.5)	25 (12.4)	0.90 (0.50–1.63)	0.73
Stillbirth*	204	207	1 (0.5)	0 (0.0)	—	—
Congenital abnormality*	201	204	6 (3.0)	10 (4.9)	1.70 (0.60–4.80)	0.32
Macrosomia (>4,000 g)*	203	206	35 (17.2)	31 (15.0)	0.85 (0.50–1.45)	0.56
Macrosomia (>4,500 g)*	203	206	2 (1.0)	7 (3.4)	—	—
Large for gestational age (>90th percentile)*	180	193	30 (16.7)	35 (18.1)	1.09 (0.64–1.88)	0.75
SGA (<2,500 g)*	203	206	6 (3.0)	7 (3.4)	1.15 (0.38–3.50)	0.81
SGA (<10th percentile)*	199	205	13 (6.5)	5 (2.4)	0.33 (0.12–0.96)	0.042
Birth weight (g)†	203	206	3,541 (514)	3,524 (540)	–15.55 (–118.24 to 87.15)	0.77
Fat-free mass (g)†	105	103	3,011 (357)	3,033 (356)	21.27 (–76.66 to 119.20)	0.67
Percentage fat†	105	105	12.3 (3.6)	12.2 (4.4)	–0.13 (–1.23 to 0.97)	0.82

*Summary columns: n (%). Effect: odds ratio. †Summary columns: mean (SD). Effect: difference of means. ‡Adjusted for BMI (25–29, 30–39, and 40+ kg/m²) and patient center (RBWH, Redcliffe, Mater).

研究结论

- ◆在这项研究中使用的益生菌未见有预防超重和肥胖孕妇发生GDM的作用。
- ◆益生菌可显著减少孕妇体重过度增长的比例，但显著增加了小于胎龄儿的比例。